Supplementary Material for Allogeneic Versus Autologous Stem-Cell Therapy: Manufacturing Costs and Commercialization Strategies - This article contains online-exclusive supplemental material for Malik

ADVERTISEMENT

Supplementary Material for Allogeneic Versus Autologous Stem-Cell Therapy: Manufacturing Costs and Commercialization Strategies
This article contains online-exclusive supplemental material for Malik's article entitled, "Allogenic Versus Autologous Stem-Cell Therapy."


BioPharm International
Volume 25, Issue 7

METHODOLOGY

Leaders in the fields of stem-cell regulation, manufacturing, and commercialization were interviewed to establish the following:

  • What a large-scale manufacturing process would be for an allogeneic therapy with stem-cell expansion and an autologous therapy with stem-cell expansion
  • The cost of each component of the manufacturing process

Selected individuals were sent an email requesting an interview. A total of 186 emails were sent, resulting in 32 individuals ultimately being interviewed (10 face-to-face, 19 by phone, and 3 via email). Interviews did not follow a rigid question format. The following four groups were interviewed:

  • Experts in the regulation of stem-cell therapies in the UK and US
  • Senior managers at leading stem-cell companies in the UK
  • Prominent academics and clinicians focusing on stem-cell therapies
  • Specialist companies focusing on specific cost components, such as the shipment of stem-cell products

COST RANGE


Table I: Cost range for each component of the manufacturing process for stem cell therapy. 1 = US $1.6.
A cost range for each component of the manufacturing process was established on the basis of minimum and maximum estimates obtained (see Table I). The cost range applies to both allogeneic and autologous therapy unless otherwise stated.

COST PER DOSE OF THERAPY


Table II: Cost to set up a manufacturing facility capable of producing 2500 doses of stem-cell therapy a year. 1 = US $1.6.
The following categories of data were calculated for allogeneic and autologous therapy:
  • The cost to set up a manufacturing facility capable of manufacturing 2500 doses of allogeneic and autologous therapy a year (see Table II).


Table III: Cost to manufacture 2,500 units of stem cell therapy a year, 1 = US $1.6.
  • The cost to manufacture 2500 doses of therapy a year (see Table III). This calculation did not take into account the cost of setting up the manufacturing facility itself. The figure obtained was divided by 2500 to obtain the manufacturing cost per dose of therapy.


Table IV: Cost to manufacture 2500 units of stem cell therapy a year factoring in the cost of setting up the manufacturing facility, 1 = US $1.6.
  • The cost to manufacture 2500 doses of therapy a year factoring in the cost of setting up the manufacturing facility (see Table IV). The calculation entailed dividing the cost to set up the manufacturing facility over its lifespan (i.e., 10 years). The manufacturing cost per dose of therapy was finally calculated.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
Author Guidelines
Source: BioPharm International,
Click here